These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 25525332)
1. Clinicopathological significance and potential drug target of RUNX3 in breast cancer. Yu YY; Chen C; Kong FF; Zhang W Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332 [TBL] [Abstract][Full Text] [Related]
2. An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis. Lu DG; Ma YM; Zhu AJ; Han YW Oncotarget; 2017 Mar; 8(13):22166-22174. PubMed ID: 27825140 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis. Xu L; Lan H; Su Y; Li J; Wan J Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616 [TBL] [Abstract][Full Text] [Related]
4. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer]. Yan Z; Gao S; Wu X; Liu H Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma. Yang Y; Ye Z; Zou Z; Xiao G; Luo G; Yang H Tumour Biol; 2014 Oct; 35(10):10333-40. PubMed ID: 25037468 [TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis. Song XY; Li BY; Zhou EX; Wu FX Onco Targets Ther; 2016; 9():5339-47. PubMed ID: 27616890 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review. Huang R; Ding P; Yang F Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077 [TBL] [Abstract][Full Text] [Related]
8. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Jiang Y; Tong D; Lou G; Zhang Y; Geng J Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070 [TBL] [Abstract][Full Text] [Related]
9. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer. Liu H; Yan Z; Yin Q; Cao K; Wei Y; Rodriguez-Canales J; Ma D; Wu Y J Histochem Cytochem; 2018 Oct; 66(10):709-721. PubMed ID: 30133331 [TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review. Su Y; Wang X; Li J; Xu J; Xu L Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255 [TBL] [Abstract][Full Text] [Related]
11. Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis. Wang Y; Qin X; Wu J; Qi B; Tao Y; Wang W; Liu F; Li H; Zhao B PLoS One; 2014; 9(9):e107598. PubMed ID: 25229459 [TBL] [Abstract][Full Text] [Related]
12. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Lau QC; Raja E; Salto-Tellez M; Liu Q; Ito K; Inoue M; Putti TC; Loh M; Ko TK; Huang C; Bhalla KN; Zhu T; Ito Y; Sukumar S Cancer Res; 2006 Jul; 66(13):6512-20. PubMed ID: 16818622 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis. Mu WP; Wang J; Niu Q; Shi N; Lian HF Onco Targets Ther; 2014; 7():1237-45. PubMed ID: 25053885 [TBL] [Abstract][Full Text] [Related]
14. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. Chen W; Gao N; Shen Y; Cen JN J Gastroenterol Hepatol; 2010 Apr; 25(4):823-31. PubMed ID: 20492341 [TBL] [Abstract][Full Text] [Related]
15. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927 [TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of runt-related transcription factor 3 gene promoter hypermethylation and risk of gastric cancer. Xia Y; Zhang M; Zhang X; Liu X J Cancer Res Ther; 2014 Dec; 10 Suppl():310-3. PubMed ID: 25693942 [TBL] [Abstract][Full Text] [Related]
17. Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells. Moon JW; Lee SK; Lee JO; Kim JH; Kim N; Kim J; Kim HS; Park SH Anticancer Res; 2014 Jan; 34(1):133-40. PubMed ID: 24403453 [TBL] [Abstract][Full Text] [Related]
18. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of determining the hypermethylation of the RUNX3 gene promoter and its cohypermethylation with the BRCA1 gene for patients with breast cancer. Rossokha Z; Fishchuk L; Lobanova O; Vershyhora V; Medvedieva N; Cheshuk V; Vereshchako R; Podolska S; Gorovenko N J Cancer Res Clin Oncol; 2023 Oct; 149(13):11919-11927. PubMed ID: 37420018 [TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]